Abstract 314P
Background
There is insufficient evidence on the neoadjuvant use of bevacizumab before interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the perioperative outcomes in a cohort of women who underwent IDS after receiving bevacizumab added to neoadjuvant chemotherapy (Bev-NACT).
Methods
We retrospectively reviewed the medical records of all women with advanced EOC who underwent IDS between March 2021 and June 2022 after receiving Bev-NACT at Tata Medical Center. Relevant information was extracted from electronic medical records. Appropriate descriptive and survival statistics were used in the analysis.
Results
A total of 33 women underwent IDS after Bev-NACT. Stage IIIC, stage IVA, and stage IVB disease were present in 51.5%, 12.1%, and 36.4% of cases. The most common histology was high-grade serous carcinoma (95%). The median number of bevacizumab cycles received was 3 (2-5). The objective response rate with Bev-NACT was 90.9%. Complete cytoreduction at IDS was achieved in 75.8%. Chemotherapy response score was 1 in 6.1%, 2 in 72.7%, and 3 in 21.2%. Surgical complications of Clavien-Dindo grade 3 or higher occurred in 24.2% of patients. Serious adverse events attributable to bevacizumab occurred in 12.1% (fistula 3%, wound complications 3%, venous thromboembolism 3%, haemorrhage 3%), and the 30-day postoperative death rate was 3%. Median progression-free survival (PFS) was 23 months (95% CI 18-34), and the estimated 3-year PFS rate was 32%.
Conclusions
Bevacizumab added to neoadjuvant chemotherapy before IDS for advanced EOC had an acceptable safety and promising efficacy. Neoadjuvant bevacizumab in advanced EOC needs to be further evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract